Pacira BioSciences, Inc.
PCRX
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.0B
$26.35
▼ -0.94%
P/E
75.24
Mkt Cap
$1.0B
52-Wk Range
$18.80–$27.66
52-Week Range
$18.80 - $27.66
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 1.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary multivesicular liposome (MVL) drug delivery technology enabling extended-release formulations
- Diversified non-opioid product portfolio addressing multiple pain management indications
- Strong clinical evidence and healthcare provider adoption in surgical and orthopedic markets
- Regulatory exclusivity and patent protection for core products
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Rising adoption of opioid-sparing pain management protocols in hospitals and surgical centers
Value
Attractively priced below Large Cap Pharma peer average
Momentum
Strong
+15.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying PCRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 4, 2026
Reported EPS of $0.73 vs $0.65 consensus (+13.0% surprise). Revenue of $192.4M vs $191.1M expected (+0.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+13.0%
Revenue trend · last 8Q
—
+3%
+1%
+2%
+6%
+5%
+5%
+6%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$168.6M
$187.3M
$168.9M
$181.1M
$179.5M
$196.9M
$177.4M
$192.4M
Margins · last 8Q
Gross
-73.3%
Operating
2.2%
Profit
2.4%
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Aug 5, 2026
vs Industry
How PCRX stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related